Menu
Menu
Exciting news! We are thrilled to welcome Amrita Hospital to our network. Based in Faridabad, India, Amrita Hospital is recognized as one of the premier healthcare institutions. The hospital improves the well-being of the local community through initiatives aimed at providing outstanding and affordable medical care in the spirit of compassion to all.
The hospital will leverage the SOPHiA DDM™ platform to further its work with rare disorders and cancers, adding exome, solid tumor, and blood cancer applications. They will be able to conduct this testing in-house, allowing for faster turnaround times for our clinicians and researchers.
Dr. Moushumi Suryavanshi, Head of Molecular Biology at Amrita Hospital, said, “As we continue to innovate and search for the best tools to bring the highest level of care for our patients, it is imperative that we offer advanced Next Generation Sequencing testing for our practices.
By adding the capabilities of SOPHiA DDM™, we will be able to find answers to complex health problems faster by keeping our samples in-house. In addition, by joining the SOPHiA GENETICS network, we will also have the opportunity to learn from a global community and be able to contribute insights found from Indian genomic data to the larger global community.”
“It is our mission to democratize data-driven medicine and bring the power of world-class technology and global insights to healthcare institutions worldwide, so we can elevate the level care for all patients. We are honored to work with Amrita Hospital to advance the field of precision medicine for their patients,” added Ricardo Ramos Mendonca Filho, PhD., Managing Director, LAPAC, SOPHiA GENETICS.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
